Study ID: TV48125-CNS-30050 | 2015-004598-34
Study Title
- Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
Teva Identifier
- TV48125-CNS-30050 | 2015-004598-34
ClinicalTrials.gov Identifier
- NCT02629861
Study Status
- Completed
Trial Condition(s)
- Migraine
Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial

Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 70 Years
Trial Duration
- March 23, 2016 - April 10, 2017
Phase
- Phase 3
Study Type
Interventional